UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Late autophagy inhibitor chloroquine improves efficacy of the histone deacetylase inhibitor SAHA and temozolomide in gliomas

Biochemical pharmacology, 2019-05, Vol.163, p.440-450

2019

Volltextzugriff (PDF)

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

Neuro-oncology (Charlottesville, Va.), 2018-03, Vol.20 (4), p.546-556

2018

Volltextzugriff (PDF)

In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals

AIDS (London), 2019-03, Vol.33 (4), p.605-613

2019

Volltextzugriff (PDF)

Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer

Biochemical pharmacology, 2020-08, Vol.178, p.114067-114067, Article 114067

2020

Volltextzugriff (PDF)

Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal

AIDS (London), 2022-01, Vol.36 (1), p.75-82

2022

Volltextzugriff (PDF)

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer

Cancer science, 2020-02, Vol.111 (2), p.561-570

2020

Volltextzugriff (PDF)

Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier

Theranostics, 2020-01, Vol.10 (6), p.2463-2478

2020

Volltextzugriff (PDF)

Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma

American journal of clinical oncology, 2019-08, Vol.42 (8), p.649-654

2019

Volltextzugriff (PDF)

Vorinostat, a histone deacetylase inhibitor, ameliorates the sociability and cognitive memory in an Ash1L-deletion-induced ASD/ID mouse model

Neuroscience letters, 2021-11, Vol.764, p.136241-136241, Article 136241

2021

Volltextzugriff (PDF)

Combinatorial antitumor effects of amino acids and epigenetic modulations in hepatocellular carcinoma cell lines

Naunyn-Schmiedeberg's archives of pharmacology, 2021-11, Vol.394 (11), p.2245-2257

2021

Volltextzugriff (PDF)

Primary Rod and Cone Degeneration Is Prevented by HDAC Inhibition

Advances in experimental medicine and biology, 2018, Vol.1074, p.367-373

2018

Volltextzugriff (PDF)

Vorinostat (SAHA) May Exert Its Antidepressant-Like Effects Through the Modulation of Oxidative Stress Pathways

Neurotoxicity research, 2021-04, Vol.39 (2), p.170-181

2021

Volltextzugriff (PDF)

Novel SAHA‑bendamustine hybrid NL‑101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia

Oncology reports, 2020-07, Vol.44 (1), p.273-282

2020

Volltextzugriff (PDF)

Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation

Oncology reports, 2019-01, Vol.41 (1), p.525-533

2019

Volltextzugriff (PDF)

Unified D-α-Tocopherol 5-Fu/SAHA bioconjugates self-assemble as complex nanodrug for optimized combination therapy

Nanomedicine (London, England), 2018-06, Vol.13 (11), p.1285-1301

2018

Volltextzugriff (PDF)

Cognitive Function and Quality of Life in Vorinostat-Treated Patients after Matched Unrelated Donor Myeloablative Conditioning Hematopoietic Cell Transplantation

Biology of blood and marrow transplantation, 2019-02, Vol.25 (2), p.343-353

2019

Volltextzugriff (PDF)

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

Journal of clinical oncology, 2017-08, Vol.35 (24), p.2745-2753

2017

Volltextzugriff (PDF)

Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice

Cell, 2014-08, Vol.158 (5), p.989-999

2014

Volltextzugriff (PDF)

Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency

The Journal of clinical investigation, 2017-08, Vol.127 (8), p.3126-3135

2017

Volltextzugriff (PDF)

Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR- Mutant Lung Cancer

Clinical cancer research, 2017-06, Vol.23 (12), p.3139-3149

2017

Volltextzugriff (PDF)

HIV-1 Expression Within Resting CD4⁺ T Cells After Multiple Doses of Vorinostat

The Journal of infectious diseases, 2014-09, Vol.210 (5), p.728-735

2014

Volltextzugriff (PDF)

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

Nature (London), 2012-07, Vol.487 (7408), p.482-485

2012

Volltextzugriff (PDF)

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature

Clinical cancer research, 2017-11, Vol.23 (21), p.6430-6440

2017

Volltextzugriff (PDF)

A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome

British journal of haematology, 2014-10, Vol.167 (2), p.185-193

2014

Volltextzugriff (PDF)

1 – 25 von 212

Suche als RSS-Feed

Aktive Filter

ThemaVorinostat

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(198)
Mit Volltextzugriff
(193)

Publikationsform

Artikel
(212)

Sprache

Englisch
(211)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(198)
Life Sciences & Biomedicine
(192)
Humans
(178)
Hydroxamic Acids - Administration & Dosage
(139)
Oncology
(117)
Female
(94)
Male
(91)
Histone Deacetylase Inhibitors - Administration & Dosage
(67)
Middle Aged
(67)
Animals
(66)
Aged
(64)
Adult
(61)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(61)
Cell Line, Tumor
(54)
Mice
(49)
Hydroxamic Acids - Pharmacology
(48)
Pharmacology & Pharmacy
(48)
Biological And Medical Sciences
(42)
Medical Sciences
(42)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Late autophagy inhibitor chloroquine improves efficacy of the histone deacetylase inhibitor SAHA and temozolomide in gliomas

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02

In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals

Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer

Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer

Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier

Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma

Vorinostat, a histone deacetylase inhibitor, ameliorates the sociability and cognitive memory in an Ash1L-deletion-induced ASD/ID mouse model

Combinatorial antitumor effects of amino acids and epigenetic modulations in hepatocellular carcinoma cell lines

Primary Rod and Cone Degeneration Is Prevented by HDAC Inhibition

Vorinostat (SAHA) May Exert Its Antidepressant-Like Effects Through the Modulation of Oxidative Stress Pathways

Novel SAHA‑bendamustine hybrid NL‑101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia

Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation

Unified D-α-Tocopherol 5-Fu/SAHA bioconjugates self-assemble as complex nanodrug for optimized combination therapy

Cognitive Function and Quality of Life in Vorinostat-Treated Patients after Matched Unrelated Donor Myeloablative Conditioning Hematopoietic Cell Transplantation

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice

Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency

Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR- Mutant Lung Cancer

HIV-1 Expression Within Resting CD4⁺ T Cells After Multiple Doses of Vorinostat

Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature

A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial

Aktive Filter

Suchergebnisse filtern